[Special Stock] Celltrion Trio Plummets on Pfizer Oral COVID-19 Treatment News
[Asia Economy Reporter Song Hwajeong] Celltrion, Celltrion Healthcare, and Celltrion Pharm are all experiencing sharp declines.
As of 9:59 AM on the 8th, Celltrion was trading at 195,000 KRW, down 14,000 KRW (6.7%) from the previous day. Celltrion Healthcare and Celltrion Pharm fell by 7.41% and 6.5%, respectively.
Hot Picks Today
There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- Kim Eo-jun Faces One-Year Prison Sentence for 'Lee Dong-jae Defamation' Charges
- Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The news of Pfizer's development of a COVID-19 treatment is interpreted to have negatively impacted their stock prices. On the 5th (local time), Pfizer announced that the trial results of its self-developed antiviral pill confirmed an effect of reducing the probability of hospitalization and death by up to 89%.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
